Autoimmunity and Cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue SUPPL.1, 2012, Pages 29-40

  Sara Achenza, M I ^a   Selmi, Carlo ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; Cancer; Epidemiology; Genetic susceptibility

Indexed keywords

EID: 84874069533     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.KKSuppl.29     Document Type: Review

References (168)

1. Abasolo L, Judez E, Descalzo MA, et al (2008). Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum, 37, 388-97.
2. Anaya JM, McGuff HS, Banks PM, Talal N (1996). Clinicopathological factors relating malignant lymphoma with sjogren's syndrome. Semin Arthritis Rheum, 25, 337-46.
3. Anderson LA, Gadalla S, Morton LM, et al (2009). Populationbased study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer, 125, 398-405.
4. Anonymous (1997). A clinical evaluation of the international lymphoma study group classification of non-hodgkin's lymphoma. The non-hodgkin's lymphoma classification project. Blood, 89, 3909-18.
5. Antiga E, Kretz CC, Klembt R, et al (2010). Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmunity, 35, 342-50.
6. Antiochos BB, Brown LA, Li Z, et al (2009). Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol, 36, 2704-10.
7. Armstrong RG, West J, Card TR (2010). Risk of cancer in inflammatorybowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol, 105, 1604-9.
8. Askling J, Baecklund E, Granath F, et al (2009). Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis, 68, 648-53.
9. Askling J, Fored CM, Baecklund E, et al (2005a). Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis, 64, 1414-20.
10. Askling J, Fored CM, Brandt L, et al (2005b). Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis, 64, 1421-6.
11. Askling J, Linet M, Gridley G, et al (2002). Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology, 123, 1428-35.
12. Asten P, Barrett J, Symmons D (1999). Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol, 26, 1705-14.
13. Baecklund E, Iliadou A, Askling J, et al (2006). Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum, 54, 692-701.
14. Beaugerie L, Brousse N, Bouvier AM, et al (2009). Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, 374, 1617-25.
15. Benyahia B, Liblau R, Merle-Beral H, et al (1999). Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol, 45, 162-7.
16. Bernatsky S, Joseph L, Boivin JF, et al (2008). The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis, 67, 74-9.
17. Bernatsky S, Lee JL, Rahme E (2007). Non-Hodgkin's lymphoma--meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology (Oxford), 46, 690-4.
18. Bernatsky S, Ramsey-Goldman R, Clarke A (2005). Malignancy risk in autoimmune rheumatic diseases. Discov Med, 5, 534-7.
19. Bernatsky S, Ramsey-Goldman R, Clarke AE (2009). Malignancy in systemic lupus erythematosus: what have we learned? Best Pract Res Clin Rheumatol, 23, 539-47.
20. Beyer M, Kochanek M, Darabi K, et al (2005). Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood, 106, 2018-25.
21. Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A (2002). Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol, 31, 66-71.
22. Bongartz T, Sutton AJ, Sweeting MJ, et al (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama, 295, 2275-85.
23. Borche L, Lim A, Binet JL, Dighiero G (1990). Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood, 76, 562-9.
24. Brito-Zeron P, Ramos-Casals M, Nardi N, et al (2005). Circulating monoclonal immunoglobulins in Sjogren syndrome: prevalence and clinical significance in 237 patients. Medicine (Baltimore), 84, 90-7.
25. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001). Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med, 134, 1087-95.
26. Burnham TK (1972). Antinuclear antibodies in patients with malignancies. Lancet, 2, 436.
27. Casciola-Rosen L, Nagaraju K, Plotz P, et al (2005). Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med, 201, 591-601.
28. Catera R, Silverman GJ, Hatzi K, et al (2008). Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med, 14, 665-74.
29. Chapman CJ, Murray A, McElveen JE, et al (2008). Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax, 63, 228-33.
30. Chen YJ, Chang YT, Wang CB, Wu CY (2010). Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med, 123, 1-6.
31. Chen YJ, Chang YT, Wang CB, Wu CY (2011). The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum, 63, 352-8.
32. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007). The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis, 66, 1345-9.
33. Chiorazzi N, Ferrarini M (2003). B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol, 21, 841-94.
34. Chiorazzi N, Rai KR, Ferrarini M (2005). Chronic lymphocytic leukemia. N Engl J Med, 352, 804-15.
35. Cibere J, Sibley J, Haga M (2001). Systemic lupus erythematosus and the risk of malignancy. Lupus, 10, 394-400.
36. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS (2002). Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum, 46, 1830-9.
37. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.
38. Czirjak L, Kumanovics G, Varju C, et al (2008). Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis, 67, 59-63.
39. Damle RN, Ghiotto F, Valetto A, et al (2002). B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood, 99, 4087-93.
40. Daridon C, Devauchelle V, Hutin P, et al (2007). Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum, 56, 1134-44.
41. Dearden C, Wade R, Else M, et al (2008). The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood, 111, 1820-6.
42. Derk CT, Rasheed M, Artlett CM, Jimenez SA (2006). A cohort study of cancer incidence in systemic sclerosis. J Rheumatol, 33, 1113-6.
43. Dreyer L, Mellemkjaer L, Andersen AR, et al (2012). Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. Ann Rheum Dis.
44. Drlicek M, Bianchi G, Bogliun G, et al (1997). Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol, 244, 85-9.
45. Ekstrom K, Hjalgrim H, Brandt L, et al (2003). Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum, 48, 963-70.
46. Fardet L, Dupuy A, Gain M, et al (2009). Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Med (Baltimore), 88, 91-7.
47. Fathallah-Shaykh H, Wolf S, Wong E, Posner JB, Furneaux HM (1991). Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA, 88, 3451-4.
48. Frenkel K, Karkoszka J, Glassman T, et al (1998). Serum autoantibodies recognizing 5-hydroxymethyl-2'- deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev, 7, 49-57.
49. Fu SM, Deshmukh US, Gaskin F (2011). Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmunity, 37, 104-12.
50. Gadalla SM, Amr S, Langenberg P, et al (2009). Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer, 100, 817-21.
51. Gasparotto D, De Vita S, De Re V, et al (2003). Extrasalivary lymphoma development in Sjogren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum, 48, 3181-6.
52. Gourh P, Agarwal SK, Martin E, et al (2010). Association of the C8orf13-BLK region with systemic sclerosis in North- American and European populations. J Autoimmunity, 34, 155-62.
53. Graus F, Dalmau J, Valldeoriola F, Ferrer I, et al (1997). Immunological characterization of a neuronal antibody (anti- Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol, 74, 55-61.
54. Groom J, Kalled SL, Cutler AH, et al (2002). Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest, 109, 59-68.
55. Gure AO, Altorki NK, Stockert E, et al (1998). Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res, 58, 1034-41.
56. Guzman LM, Castillo D, Aguilera SO (2010). Polymerase chain reaction (PCR) detection of B cell clonality in Sjogren's syndrome patients: a diagnostic tool of clonal expansion. Clin Exp Immunol, 161, 57-64.
57. Haga HJ, Eide GE, Brun J, Johansen A, Langmark F (1993). Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol, 20, 1335-9.
58. Hall AM, Vickers MA, McLeod E, Barker RN (2005). Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood, 105, 2007-15.
59. Hamblin TJ (2006). Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol, 33, 230-9.
60. Hellgren K, Iliadou A, Rosenquist R, et al (2010). Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis, 69, 654-9.
61. Hemminki K, Li X, Sundquist J, Sundquist K (2008a). Cancer risks in ulcerative colitis patients. Int J Cancer, 123, 1417-21.
62. Hemminki K, Li X, Sundquist J, Sundquist K (2009). Cancer risks in Crohn disease patients. Ann Oncol, 20, 574-80.
63. Hemminki K, Li X, Sundquist K, Sundquist J (2008b). Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford), 47, 698-701.
64. Herbst H, Sauter M, Mueller-Lantzsch N (1996). Expression of human endogenous retrovirus K elements in germ cell and trophoblastic tumors. Am J Pathol, 149, 1727-35.
65. Herrmann M, Hagenhofer M, Kalden JR (1996). Retroviruses and systemic lupus erythematosus. Immunol Rev, 152, 145-56.
66. Herve M, Xu K, Ng YS, et al (2005). Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest, 115, 1636-43.
67. Hill CL, Zhang Y, Sigurgeirsson B, et al (2001). Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet, 357, 96-100.
68. Hodgson K, Ferrer G, Montserrat E, Moreno C (2011). Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica, 96, 752-61.
69. Imai H, Ochs RL, Kiyosawa K, et al (1992). Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol, 140, 859-70.
70. Iobagiu C, Magyar A, Nogueira L, et al (2011). The antigen specificity of the rheumatoid arthritis-associated ACPA directed to citrullinated fibrin is very closely restricted. J Autoimmunity, 37, 263-72.
71. Jager D, Stockert E, Gure AO, et al (2001). Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res, 61, 2055-61.
72. Jianguang Ji XL, Kristina S, Jan S, Hemmink K (2010). Cancer risk in patients hospitalized with polymyalgiarheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology (Oxford), 49, 1158-63.
73. Jordan RC, Odell EW, Speight PM (1996). B-cell monoclonality in salivary lymphoepithelial lesions. Eur J Cancer B Oral Oncol, 32, 38-44.
74. Kafantari E, Sotiropoulou M, Sfikakis P, et al (2008). Giant cell arteritis of the breast and breast cancer: paraneoplastic manifestation or concomitant disease? A case report. Onkologie, 31, 685-8.
75. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD (2005). Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut, 54, 1121-5.
76. Kang KY, Kim HO, Yoon HS, et al (2010). Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol, 29, 381-8.
77. Kang KY, Yim HW, Kim IJ, et al (2009). Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol, 38, 299-303.
78. Kapsogeorgou EK, Gourzi VC, Manoussakis MN, Moutsopoulos HM, Tzioufas AG (2011). Cellular microRNAs (miRNAs) and Sjogren's syndrome: candidate regulators of autoimmune response and autoantigen expression. J Autoimmunity, 37, 129-35.
79. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, et al (1978). Increased risk of lymphoma in sicca syndrome. Ann Intern Med, 89, 888-92.
80. Kauppi M, Pukkala E, Isomaki H (1997). Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control, 8, 201-4.
81. Keith MP, Gilliland WR (2006). Polymyalgia rheumatica and breast cancer. J Clin Rheumatol, 12, 199-200.
82. Kipps TJ, Carson DA (1993). Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood, 81, 2475-87.
83. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, et al (2001). Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med, 194, 1625-38.
84. Kontaki E, Boumpas DT (2010). Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. Journal of autoimmunity, 35, 206-11.
85. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, et al (2011). A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 9, 36-41 e1.
86. Kountourakis P, Arnogiannaki N, Stavrinides I, Apostolikas N, Rigatos G (2008). Concomitant gastric adenocarcinoma and stromal tumor in a woman with polymyalgia rheumatica. World J Gastroenterol, 14, 6750-2.
87. Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, et al (2011). Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol, 165, 1273-9.
88. Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, et al (2011). Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer, 117, 1163-71.
89. Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, et al (2006). Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst, 98, 1321-30.
90. Limaye V, Luke C, Tucker G, Hill C, Lester S, et al (2012). The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int.
91. Lofstrom B, Backlin C, Sundstrom C, Ekbom A, Lundberg IE (2007). A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis.
92. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, et al (2012). Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a metaanalysis. Jama, 308, 898-908.
93. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, et al (1995). p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res, 1, 1463-9.
94. Lucchinetti CF, Kimmel DW, Lennon VA (1998). Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology, 50, 652-7.
95. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M (2007). Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr, 44, 265-7.
96. Manoussakis MN, Spachidou MP, Maratheftis CI (2010). Salivary epithelial cells from Sjogren's syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation. J Autoimmunity, 35, 212-8.
97. Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer related inflammation. Nature, 454, 436-44.
98. Mariette X, Matucci-Cerinic M, Pavelka K, et al (2011). Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis, 70, 1895-904.
99. Mariette X, Roux S, Zhang J, et al (2003). The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis, 62, 168-71.
100. Mavragani CP, Crow MK (2010). Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmunity, 35, 225-31.
101. Mellemkjaer L, Pfeiffer RM, Engels EA, et al (2008). Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum, 58, 657-66.
102. Molberg O, Solheim Flaete N, Jensen T, et al (2003). Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology, 125, 337-44.
103. Moreno C, Hodgson K, Ferrer G, et al (2010). Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood, 116, 4771-6.
104. Myint H, Copplestone JA, Orchard J, et al (1995). Fludarabinerelated autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol, 91, 341-4.
105. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT (2002). No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol, 29, 2143-7.
106. Naschitz JE, Slobodin G, Yeshurun D, Rozenbaum M, Rosner I (1996). A polymyalgia rheumatica-like syndrome as presentation of metastatic cancer. J Clin Rheumatol, 2, 305-8.
107. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M (2008). Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. Rheumatology (Oxford), 47, 1311-6.
108. Ognenovski VM, Marder W, Somers EC, et al (2004). Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol, 31, 1763-7.
109. Old LJ, Chen YT (1998). New paths in human cancer serology. J Exp Med, 187, 1163-7.
110. Olesen AB, Svaerke C, Farkas DK, Sorensen HT (2010). Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol, 163, 800-6.
111. Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED (2011). Hepatosplenic T-cell lymphoma in patients receiving TNFalpha inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol, 23, 1150-6.
112. Parikh-Patel A, White RH, Allen M, Cress R (2008). Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control, 19, 887-94.
113. Raaschou P, Simard JF, Neovius M, Askling J (2011). Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum, 63, 1812-22.
114. Roguedas AM, Pers JO, Lemasson G, et al (2010). Memory B-cell aggregates in skin biopsy are diagnostic for primary Sjogren's syndrome. J Autoimmunity, 35, 241-7.
115. Royer B, Cazals-Hatem D, Sibilia J, et al (1997). Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood, 90, 766-75.
116. Sahin U, Tureci O, Schmitt H, et al (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA, 92, 11810-3.
117. Salliot C, van der Heijde D (2009). Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis, 68, 1100-4.
118. Salloum E, Cooper DL, Howe G, et al (1996). Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol, 14, 1943-9.
119. Sartor RB (2006). Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol, 3, 390-407.
120. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002). Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev, 188, 22-32.
121. Sellam J, Miceli-Richard C, Gottenberg JE, et al (2007). Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis, 66, 790-7.
122. Setoguchi S, Solomon DH, Weinblatt ME, et al (2006). Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum, 54, 2757-64.
123. Shah AA, Rosen A (2011). Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol, 23, 530-5.
124. Shiel WC, Jason M (1989). The diagnostic associations of patients with antinuclear antibodies referred to a community rheumatologist. J Rheumatol, 16, 782-5.
125. Siau K, Laversuch CJ, Creamer P, O'Rourke KP (2011). Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int, 31, 641-5.
126. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE (2009). Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol, 7, 874-81.
127. Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992). Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med, 326, 363-7.
128. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM (2000). Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum, 29, 296-304.
129. Smedby KE, Hjalgrim H, Askling J, et al (2006). Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst, 98, 51-60.
130. Smith RE, Bryant J, DeCillis A, Anderson S (2003). Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol, 21, 1195-204.
131. Soderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M (2006). Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer, 42, 3028-33.
132. Solans-Laque R, Perez-Bocanegra C, Salud-Salvia A, Fonollosa- Pla V, Rodrigo MJ, et al (2004). Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus, 13, 159-64.
133. Somers K, Geusens P, Elewaut D, et al (2011). Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmunity, 36, 33-46.
134. Soussi T (2000). p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res, 60, 1777-88.
135. Sutcliffe N, Inanc M, Speight P, Isenberg D (1998). Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum, 28, 80-7.
136. Szekanecz E, Szamosi S, Gergely L, et al (2008). Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol, 27, 1163-6.
137. Takada K, Illei GG, Boumpas DT (2001). Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus, 10, 154-61.
138. Takagi K, Kawaguchi Y, Kawamoto M, et al (2011). Activation of the activin A-ALK-Smad pathway in systemic sclerosis. J Autoimmunity, 36, 181-8.
139. Tam LS, Chan AY, Chan PK, Chang AR, Li EK (2004). Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum, 50, 3619-25.
140. Tapinos NI, Polihronis M, Moutsopoulos HM (1999). Lymphoma development in Sjogren's syndrome: novel p53 mutations. Arthritis Rheum, 42, 1466-72.
141. Theander E, Henriksson G, Ljungberg O, et al (2006). Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis, 65, 796-803.
142. Tobon GJ, Youinou P, Saraux A (2010). The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. J Autoimmunity, 35, 10-4.
143. Tosti S, Caruso R, D'Adamo F, et al (1992). Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol, 65, 238-9.
144. Trallero-Araguas E, Labrador-Horrillo M, Selva-O'Callaghan A, et al (2010). Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore), 89, 47-52.
145. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, et al (2012). Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum, 64, 523-32.
146. Travis LB, Curtis RE, Glimelius B, et al (1995). Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst, 87, 524-30.
147. Tureci O, Sahin U, Vollmar E, et al (1998). Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA, 95, 7608-13.
148. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM (1996). Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum, 39, 767-72.
149. Tzioufas AG, Katsikis PD, Youinou PY, Moutsopoulos HM (1990). Sjogren's syndrome: an oligo-monoclonal B cell process. Clin Exp Rheumatol, 8, 17-21.
150. Van der Bruggen P SV, Vigneron N, Van den Eynde B (2012). Peptide database: T cell-defined tumor antigens. Cancer Immun.
151. Varin MM, Le Pottier L, Youinou P, et al (2010). B-cell tolerance breakdown in Sjogren's syndrome: focus on BAFF. Autoimmun Rev, 9, 604-8.
152. Vincent FB, Morand EF, Mackay F (2012). BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol, 90, 293-303.
153. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999). Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum, 42, 1765-72.
154. Voulgarelis M, Skopouli FN (2007). Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol, 32, 265-74.
155. Voulgarelis M, Tzioufas AG (2010). Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol, 6, 529-37.
156. Voulgarelis M, Tzioufas AG, Moutsopoulos HM (2001). Monoclonal expansion of B cells in Sjogren's syndrome: comment on the article by Martin et al. Arthritis Rheum, 44, 490.
157. Wakata N, Kurihara T, Saito E, Kinoshita M (2002). Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol, 41, 729-34.
158. Walters MT, Stevenson FK, Herbert A, Cawley MI, Smith JL (1986). Urinary monoclonal free light chains in primary Sjogren's syndrome: an aid to the diagnosis of malignant lymphoma. Ann Rheum Dis, 45, 210-9.
159. Wasserman J, Glas U, Blomgren H (1975). Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis. Clin Exp Immunol, 19, 417-22.
160. Whitehouse JM, Holborow EJ (1971). Smooth muscle antibody in malignant disease. Br Med J, 4, 511-3.
161. Wolfe F, Michaud K (2004). Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum, 50, 1740-51.
162. Wolfe F, Michaud K (2007). Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum, 56, 2886-95.
163. Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST (2011). Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol, 31, 631-6.
164. Yamada T, Nakajima A, Inoue E, et al (2011). Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int, 31, 1487-92.
165. Zampieri S, Doria A, Adami N, et al (2010a). Subclinical myopathy in patients affected with newly diagnosed colorectal cancer at clinical onset of disease: evidence from skeletal muscle biopsies. Neurol Res, 32, 20-5.
166. Zampieri S, Valente M, Adami N, et al (2010b). Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev, 9, 449-53.
167. Zantos D, Zhang Y, Felson D (1994). The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol, 21, 1855-9.
168. Zuber M (1992). Positive antinuclear antibodies in malignancies. Ann Rheum Dis, 51, 573-4.